Actively Recruiting

All Genders
NCT07109154

DeniLA: Comprehensive Demographics and Clinical Profile of NSCLC Patients: Analyzing Guideline-Concordant Care in First-line Treatment Patterns

Led by AstraZeneca · Updated on 2026-05-13

200

Participants Needed

7

Research Sites

74 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a prospective, observational, multicenter study, in which clinical and demographic data will be extracted from medical records. Convenience sample, with an estimated inclusion of 200 patients treated in seven participating centers. Eligible tumors for this project will be from patients with advanced (unresectable or metastatic) non-small cell lung carcinoma, who will start first-line oncological treatment in one of the participating centers between 2025 and 2026 (between January 2025 and January 2026). Patients must be over 18 years old and data must be available in electronic medical records. Medical records will be assessed to confirm patients' eligibility. Patients with localized disease amenable to local treatment, non-epithelial histology, small cell carcinoma and neuroendocrine tumor will not be eligible. A survey will be designed targeting thoracic and generalist medical oncologists, aiming to understand the factors guiding the choice of first-line treatment regimens and to compare these insights with real-world data. The survey will be directed to Brazil, with an estimated of 200 filled files.

CONDITIONS

Official Title

DeniLA: Comprehensive Demographics and Clinical Profile of NSCLC Patients: Analyzing Guideline-Concordant Care in First-line Treatment Patterns

Who Can Participate

All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Advanced (unresectable or metastatic) non-small cell lung carcinoma
  • Starting first-line oncological treatment in a participating center between January 2025 and January 2026
  • Over 18 years old
  • Data available in electronic medical records
Not Eligible

You will not qualify if you...

  • Localized disease amenable to local treatment
  • Non-epithelial histology
  • Small cell carcinoma
  • Neuroendocrine tumor
  • Patients with unresectable NSCLC treated with the PACIFIC protocol and currently followed up

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 7 locations

1

Research Site

Recife, Brazil

Active, Not Recruiting

2

Research Site

Rio de Janeiro, Brazil

Actively Recruiting

3

Research Site

Rio de Janeiro, Brazil

Not Yet Recruiting

4

Research Site

Salvador, Brazil

Actively Recruiting

5

Research Site

Salvador, Brazil

Not Yet Recruiting

6

Research Site

São Paulo, Brazil

Active, Not Recruiting

7

Research Site

São Paulo, Brazil

Not Yet Recruiting

Loading map...

Research Team

A

AstraZeneca Clinical Study Information Center

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

DeniLA: Comprehensive Demographics and Clinical Profile of NSCLC Patients: Analyzing Guideline-Concordant Care in First-line Treatment Patterns | DecenTrialz